Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist

Pharmacology Biochemistry and Behavior

Volumn 96, Issue 2, 2010, Pages 175-180

  Ohno, Yukihiro ^a   Okano, Motoki ^a   Imaki, Junta ^a   Tatara, Ayaka ^a   Okumura, Takahiro ^a   Shimizu, Saki ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Antipsychotics; Blonanserin; Extrapyramidal side effects; Fos expression; Nucleus accumbens; Striatum

Indexed keywords

AD 6048; BLONANSERIN; DRUG METABOLITE; HALOPERIDOL; PROTEIN FOS; UNCLASSIFIED DRUG; DOPAMINE 2 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN C FOS; PYRIDINE DERIVATIVE; SEROTONIN 2 ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRADYKINESIA; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG STRUCTURE; EXTRAPYRAMIDAL SYMPTOM; FOREBRAIN; MALE; MOUSE; NEUROMODULATION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG INTERACTION; DYSKINESIA, DRUG-INDUCED; INBRED MOUSE STRAIN; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; CATALEPSY; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; MALE; MICE; MICE, INBRED STRAINS; NUCLEUS ACCUMBENS; PIPERAZINES; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-FOS; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; DOPAMINE D2 RECEPTOR ANTAGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

MUS;

EID: 77953716951     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.04.027     Document Type: Article

References (36)

1. Bleich A., Brown S.L., Kahn R., van Praag H.M. The role of serotonin in schizophrenia. Schizophr Bull 1988, 14:297-315.
2. Chartoff E.H., Ward R.P., Dorsa D.M. Role of adenosine and N-methyl-D-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy. J Pharmacol Exp Ther 1999, 291:531-537.
3. Crow T.J. The two-syndrome concept: origins and current status. Schizophr Bull 1985, 11:471-486.
4. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 2008, Academic Press/Elsevier, New York. 3rd ed.
5. Garcia E., Robert M., Peris F., Nakamura H., Sato N., Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs 2009, 23:615-625.
6. 3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol 2007, 572:171-174.
7. Gyertyán I., Sághy K., Laszy J., Elekes O., Kedves R., Gémesi L.I., et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. Behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol 2008, 378:529-539.
8. 1A receptors. Biog Amines 2004, 18:307-318.
9. Ishibashi T., Ikeda K., Ishida K., Yasui J., Tojima R., Nakamura M., et al. Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum. Eur J Pharmacol 1996, 303:247-251.
10. 2 receptor antagonist, on Fos protein expression in the rat forebrain. Pharmacol Biochem Behav 1999, 63:535-541.
11. 3H]acetylcholine release from rat striatal slices. Gen Pharmacol 1996, 27:1203-1207.
12. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996, 153:466-476.
13. Lewine R.R., Fogg L., Meltzer H.Y. Assessment of negative and positive symptoms in schizophrenia. Schizophr Bull 1983, 9:368-376.
14. Marchant K.M., Dorsa D.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc Natl Acad Sci U S A 1993, 90:3447-3451.
15. Meltzer H.Y., Nash J.F. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 1991, 43:587-604.
16. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:1159-1172.
17. 1A receptors. J Pharmacol Exp Ther 2000, 295:853-861.
18. 3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur J Pharmacol 1997, 321:403-405.
19. Nagai T., Noda Y., Une T., Furukawa K., Furukawa H., Kan Q.M., et al. Effects of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice. NeuroReport 2003, 14:269-272.
20. Noda Y., Kurumiya S., Miura Y., Oka M. Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5, 6, 7, 8, 9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects. J Pharmacol Exp Ther 1993, 265:745-751.
21. Noda Y., Kamei H., Mamiya T., Furukawa H., Nabeshima T. Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 2000, 23:375-387.
22. 2 receptor antagonist, using the mouse pole test. Pharmacol Biochem Behav 1994, 49:19-23.
23. 2 antagonist, on dopamine and 5-HT receptors in rats. Prog Neuropsychopharmacol Biol Psychiatry 1995, 19:1091-1101.
24. Ohno Y., Ishibashi T., Okada K., Ishida K., Nakamura M. Effects of chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral dopaminergic and serotonergic sensitivities in rats. Gen Pharmacol 1995, 26:489-494.
25. 2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone. Pol J Pharmacol 1997, 49:213-219.
26. 1A agonists using the mouse pole test. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1302-1307.
27. Ohno Y., Shimizu S., Imaki J., Ishihara S., Sofue N., Sasa M., et al. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology 2008, 55:717-723.
28. 1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice. J Pharmacol Sci 2009, 109:593-599.
29. 2 antagonist properties. J Pharmacol Exp Ther 1993, 264:158-165.
30. Oka T., Hamamura T., Lee Y., Miyata S., Habara T., Endo S., et al. Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain. Life Sci 2004, 76:225-237.
31. 3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997, 280:73-82.
32. Raedler T.J., Knable M.B., Jones D.W., Urbina R.A., Egan M.F., Weinberger D.R. Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology 2003, 28:1531-1537.
33. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 1992, 46:315-328.
34. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994, 271:1058-1066.
35. Saller C.F., Czupryna M.J., Salama A.I. 5-HT2 receptor blockade by ICI 169, 369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade. J Pharmacol Exp Ther 1990, 253:1162-1170.
36. Une T., Kurumiya S. Pharmacological profile of blonanserin. Jpn J Clin Psychopharmacol 2007, 10:1263-1272.